{"preliminary_commentary":{"by_channel":{"x_thread":10,"youtube":2,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06150417\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[],"indication":"de novo oligometastatic prostate cancer","name":"METANOVA","nct_id":"NCT06150417","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=metanova-nct06150417. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"* Participants will receive the standard of care. Standard systemic therapy (SST) and definitive local therapy (radiotherapy \\[RT\\] or radical prostatectomy \\[RP\\]) are the standard of care for de novo oligometastatic prostate cancer. This arm will be used to compare to the experimental arm.\n* SST will begin 6 weeks of randomization and occur for 12 months. The definitive local therapy will be RT, with a small portion undergoing RP. Local therapy should be completed by the end of Week 20.","label":"Standard of Care (SOC)","type":"ACTIVE_COMPARATOR"},{"description":"* Participants will receive the standard of care. Standard systemic therapy (SST) and definitive local therapy (radiotherapy \\[RT\\] or radical prostatectomy \\[RP\\]) are the standard of care for de novo oligometastatic prostate cancer. This arm will be used to compare to the experimental arm.\n* SST will begin 6 weeks of randomization and occur for 12 months. The definitive local therapy will be RT, with a small portion undergoing RP. Local therapy should be completed by the end of Week 20.\n* MDRT should be completed by the end of Week 24. Depending on the participant, there are different approaches to MDRT dosing and fraction size.","label":"SOC + MDRT","type":"EXPERIMENTAL"}],"collaborators":["National Institutes of Health (NIH)","National Cancer Institute (NCI)"],"completion_date":{"date":"2028-12-01","type":"ESTIMATED"},"conditions":["Prostate Cancer","Malignant Neoplasm of Prostate","Secondary Malignant Neoplasm of Prostate"],"enrollment":{"count":200,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Androgen deprivation therapy (ADT)","otherNames":[],"type":"DRUG"},{"name":"Androgen receptor signaling inhibitor (ARSI)","otherNames":[],"type":"DRUG"},{"name":"Local Therapy: Radical Prostatectomy (RP) or Radiotherapy (RT)","otherNames":[],"type":"OTHER"},{"name":"Metastasis directed radiotherapy (MDRT)","otherNames":[],"type":"RADIATION"}],"last_update":"2026-09-15","lead_sponsor":"Case Comprehensive Cancer Center","official_title":"Metastasis-directed Radiotherapy (MDRT) for Men With De-novo Oligometastatic Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2028-12-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Failure-free survival (FFS)","timeFrame":"Up to 5 years from treatment"}],"references":[{"citation":"Lichtman-Mikol S, Lang JM, Nagar H, Zuhour R, Chaung KV, Zaorsky NG, Roy S, Mendiratta PM, Shoag JE, Janopaul-Naylor JR, Khani F, Schaeffer EM, Kyriakopoulos CE, Barata P, Brown JR, Garcia JA, Barbieri CE, Sun Y, Choyke PL, Spratt DE, Jia AY. Metastasis-directed radiotherapy (MDRT) for men with de novo, oligometastatic prostate cancer treated with long-term androgen deprivation therapy in the STAMPEDE trial (METANOVA): protocol for a multicentre, phase II randomised controlled trial in the USA. BMJ Open. 2026 Oct 6;16(10):e116331. doi: 10.1136/bmjopen-2026-116331.","pmid":"42838582","type":"DERIVED"}],"start_date":{"date":"2024-07-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)","url":"https://clinicaltrials.gov/study/NCT06150417"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/metanova-nct06150417"}